טוען...
New Developments in the Treatment of X-Linked Hypophosphataemia: Implications for Clinical Management
X-linked hypophosphataemia (XLH) is due to mutations in phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) and represents the most common heritable form of rickets. In this condition, the hormone fibroblast growth factor 23 (FGF23) is produced in excessive amounts...
שמור ב:
| הוצא לאור ב: | Paediatr Drugs |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer International Publishing
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7083817/ https://ncbi.nlm.nih.gov/pubmed/31965544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40272-020-00381-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|